Effect of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) on Weight Loss Following Bariatric Treatment
Pooled result · Weight change, observational studiesResult — go to the resultAbsolute difference −7.83 kg 95% CI −9.27 to −6.38Authors' conclusion
Our findings suggest that the use of liraglutide and semaglutide in patients who previously underwent MBS can promote significant weight reduction with an acceptable safety profile.
Study context
- Population
- Patients who previously underwent metabolic bariatric surgery (MBS)
- Participants
- 1,164 patients17 studies
- Comparison
- GLP-1 RA vs pre-treatment baseline or vs control/placebo
- Outcome
- Absolute difference in body weight (kg) vs baseline (observational studies) or vs control (RCTs)
Methodological detailsrandom-effects model, observational studies and randomized controlled trials (RCTs)
- Random-effects model
- Observational studies and RCTs
Pooled result
Weight change, observational studies
Absolute difference
−7.83 kg
95% CI −9.27 to −6.38
GLP-1RAvs Pre treatment
absolute difference −7.83 kg (95% CI −9.27 to −6.38)
As reported in the abstract
Further pooled results
| Outcome | Weight reduction (kg) (95% CI) |
|---|---|
| Weight change, RCTsReduction with GLP-1RA | 4.36 (−0.42 to −8.30) |
Safety
Tolerability
- Any adverse event (observational studies)
- 23% (95% CI, 10%-36%)
- Discontinued treatment
- 7%
- RCTs: safety profile similar to placebo
Original publication
Effect of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) on Weight Loss Following Bariatric Treatment. J Clin Endocrinol Metab. Published 15 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →